Wells Fargo lowered the firm’s price target on Baxter (BAX) to $33 from $36 and keeps an Equal Weight rating on the shares. The firm notes the company delivered a good start to FY25 with strong Novum IQ adoption, early recovery in IV solutions, and resilient capital trends. On tariffs, Baxter will absorb $60M-$70M headwind to FY25 margins/EPS, Wells adds.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter International: Balancing Growth Potential and Tariff Challenges with a Hold Rating
- Baxter International Reports Strong Q1 2025 Results
- Baxter International Surpasses Q1 2025 Expectations
- Balanced Outlook on Baxter International: Strong Performance with Margin Concerns
- Baxter reports Q1 adjusted EPS 62c, consensus 48c